GnRH-a预处理时长与来曲唑补充对子宫腺肌症冻融胚胎移植活产率的影响:GOLD-FET多中心2×2析因随机对照试验方案
本研究为在中国3个生殖医学中心开展的多中心、开放标签、2×2析因设计优效性随机对照试验,计划纳入432例20-38岁超声诊断子宫腺肌症、拟行单囊胚冻融胚胎移植的女性。受试者按1:1:1:1随机分为四组:单剂GnRH-a(3.75 mg)、双剂GnRH-a、单剂GnRH-a联合来曲唑(2.5 mg每日共28天)、双剂GnRH-a联合来曲唑。主要结局为活产率,旨在比较不同GnRH-a剂量联合或不联合来曲唑对妊娠结局的影响。
要点
- 比较单剂与双剂GnRH-a预处理对子宫腺肌症患者FET活产率的影响。
- 评估来曲唑(2.5 mg每日共28天)联合GnRH-a能否改善妊娠结局。
- 采用2×2析因设计,可同时评估两因素及其交互作用。
核心结论
- 该试验旨在明确子宫腺肌症患者FET前GnRH-a预处理的最佳剂量以及来曲唑补充的协同效应,为优化预处理策略提供高级别证据。
研究设计与样本
- 多中心、开放标签、2×2析因设计、优效性随机对照试验,在中国3个生殖医学中心开展。
- 计划纳入432例20-38岁超声诊断子宫腺肌症、拟行单囊胚冻融胚胎移植的女性。
- 按1:1:1:1随机分为四组:单剂GnRH-a(3.75 mg)、双剂GnRH-a、单剂GnRH-a联合来曲唑(2.5 mg每日共28天)、双剂GnRH-a联合来曲唑。
- 主要结局为活产率;次要结局包括生育结局、妊娠与产科结局及新生儿结局。
- 每组约25例时进行内部预试验评估程序可行性;随访至产后6个月。
关键数值与推荐
- GnRH-a单剂剂量为3.75 mg;来曲唑为2.5 mg每日共28天。
- 主要结局为活产率,试验设计为优效性检验。
- 安全性结局包括低雌激素相关不良事件(如潮热、骨丢失、阴道干涩)的发生率与严重程度及其他严重不良事件。
临床怎么用
- 若试验证实双剂GnRH-a或联合来曲唑可提高活产率,可为子宫腺肌症患者FET前预处理方案提供循证依据。
- 安全性数据有助于评估延长GnRH-a预处理或联合来曲唑对低雌激素相关不良事件的影响。
局限性
- 开放标签设计可能引入实施偏倚。
- 研究仅纳入20-38岁、单囊胚移植的子宫腺肌症患者,外推性受限。
- 目前仅为研究方案,尚无结局数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Adenomyosis, an estrogen-dependent condition characterized by endometrial invasion into the myometrium, is associated with reduced live birth rates and increased miscarriage risk in women undergoing assisted reproductive technologies (ART). Gonadotropin-releasing hormone agonists (GnRH-a) are commonly used for pretreatment before frozen-thawed embryo transfer (FET) in adenomyosis patients, but optimal duration remains unclear. Letrozole, an aromatase inhibitor, may enhance GnRH-a efficacy by mitigating its flare-up effect and reducing peripheral estrogen production, yet high-level evidence on their combined effect is lacking. This study aims to compare the live birth rate and other pregnancy outcomes between one and two doses of GnRH-a pretreatment with or without letrozole supplementation in women with adenomyosis undergoing FET. METHODS: This is a 2 × 2 factorial, multi-center, open-label, randomized controlled trial (RCT) conducted at three reproductive medical centers in China, with a planned enrollment of 432 women aged 20-38 years with sonographically diagnosed adenomyosis scheduled for single blastocyst FET. This study is designed as a superiority trial. Recruitment will be conducted by trained clinical research coordinators. Participants are randomized in a 1:1:1:1 ratio to four arms: one dose of GnRH-a (3.75 mg), two doses of GnRH-a, one dose of GnRH-a with letrozole (2.5 mg daily for 28 days), or two doses of GnRH-a with letrozole (2.5 mg daily for 28 days). The primary outcome is live birth rate. Secondary outcomes include fertility outcomes, pregnancy and obstetric outcomes, and neonatal outcomes. Safety outcomes, including the incidence and severity of low-estrogen-related adverse events (e.g., hot flashes, bone loss, vaginal dryness) and other serious adverse events, will be collected and compared. An internal pilot phase will assess procedural feasibility when approximately 25 participants are randomized per arm. Data are collected via medical records and follow-up assessments up to 6 months postpartum. DISCUSSION: This factorial RCT is the first to assess the synergistic effects of GnRH-a dosage and letrozole supplementation, overcoming limitations of single-factor studies. By comprehensively evaluating pregnancy outcomes, the study aims to optimize pretreatment strategies, inform clinical guidelines, and improve pregnancy outcomes for adenomyosis patients undergoing FET. TRIAL REGISTRATION: ClinicalTrials.gov NCT07065539. Registered on 14 July 2025. https://clinicaltrials.gov/study/NCT07065539 . The first participant was enrolled in August 2025.
引用
- Xiong Y, Gu F, Du L, et al. Gonadotropin-releasing hormone agonist (GnRH-a) pretreatment duration and letrozole supplementation for optimizing live birth rates in women with adenomyosis undergoing frozen-thawed embryo transfer (GOLD-FET): study protocol for a multicenter, 2 × 2 factorial randomized controlled trial in China. Trials. 2026. PMID: 42032741. doi:10.1186/s13063-026-09731-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。